Anthracyclines in the treatment of cancer. An overview

Drugs

Volumn 54, Issue SUPPL. 4, 1997, Pages 1-7

  Hortobagyi G N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; GLYCOPROTEIN P; HYDROXYL RADICAL; IDARUBICIN; ISOMERASE INHIBITOR; LIPOSOME; RAZOXANE; VINCRISTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BASE PAIRING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RESISTANCE; DRUG TOLERABILITY; DRUG TUMOR LEVEL; ENCAPSULATION; ENZYME INHIBITION; HEART; HEART PROTECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NEUTROPENIA; REVIEW; SOLID TUMOR; STOMATITIS; STRUCTURE ACTIVITY RELATION; TISSUE INJURY; TUMOR RESISTANCE; VOMITING;

EID: 0030713362     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199700544-00003     Document Type: Review

References (53)

1. 1. K Mross 1991 New anthracycline derivatives: what for? Eur J Cancer 27 12 1542 4 1782058 10.1016/0277-5379(91)90409-7 1:STN:280:DyaK387ksVaiug%3D%3D Mross K. New anthracycline derivatives: what for? Eur J Cancer 1991; 27(12): 1542–4
2. 2. RB Weiss 1992 The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19 6 670 86 1462166 1:CAS:528:DyaK3sXhtl2jsbo%3D Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19(6): 670–86
3. 3. DJ Booser GN Hortobágyi 1994 Anthracycline antibiotics in cancer therapy: focus on drug resistance Drugs 47 2 223 58 7512899 10.2165/00003495-199447020-00002 1:STN:280:DyaK2c3hsFGjuw%3D%3D Booser DJ, Hortobágyi GN. Anthracycline antibiotics in cancer therapy: focus on drug resistance. Drugs 1994; 47(2): 223–58
4. 4. R Abraham RL Basser MD Green 1996 A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy Drug Saf 15 6 406 29 8968695 10.2165/00002018-199615060-00005 1:CAS:528:DyaK2sXjtFOktg%3D%3D Abraham R, Basser RL, Green MD. A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy. Drug Saf 1996; 15(6): 406–29
5. 5. VD Meriweather NR Bachur 1972 Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia Cancer Res 32 1137 42 Meriweather VD, Bachur NR. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res 1972; 32: 1137–42
6. 6. KE Reinert 1983 Anthracycline-binding induced DNA stiffening, bending and elongation: stereochemical implications from viscometric investigations Nucleic Acids Res 11 3411 40 6574425 10.1093/nar/11.10.3411 1:CAS:528:DyaL3sXks1Kjtbg%3D Reinert KE. Anthracycline-binding induced DNA stiffening, bending and elongation: stereochemical implications from viscometric investigations. Nucleic Acids Res 1983; 11: 3411–40
7. 7. BK Sinha AG Katki G Batist 1987 Adriamycin-stimulated hydroxyl formation in human breast tumour cells Biochem Pharmacol 36 793 6 3032195 10.1016/0006-2952(87)90164-X 1:CAS:528:DyaL2sXktVSgtbc%3D Sinha BK, Katki AG, Batist G, et al. Adriamycin-stimulated hydroxyl formation in human breast tumour cells. Biochem Pharmacol 1987; 36: 793–6
8. 8. RT Dorr 1996 Cytoprotective agents for anthracyclines Semin Oncol 23 Suppl.8 23 34 8783663 1:CAS:528:DyaK28XmsFCmtL8%3D Dorr RT. Cytoprotective agents for anthracyclines. Semin Oncol 1996; 23Suppl. 8: 23–34
9. 9. R Larsson P Nygren 1994 Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors Cancer 74 2857 62 7954248 10.1002/1097-0142(19941115)74:10<2857::AID-CNCR2820741019>3.0.CO;2-5 1:STN:280:DyaK2M%2Fkt1Wgtw%3D%3D Larsson R, Nygren P. Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors. Cancer 1994; 74: 2857–62
10. 10. T Efferth R Osieka 1993 Clinical relevance of the MDR-1 gene and its gene product, P-glycoprotein, for cancer chemotherapy: a meta-analysis Tumor Diagn Ther 14 238 43 Efferth T, Osieka R. Clinical relevance of the MDR-1 gene and its gene product, P-glycoprotein, for cancer chemotherapy: a meta-analysis. Tumor Diagn Ther 1993; 14: 238–43
11. 11. A Goldhirsch WC Wood H-J Senn 1995 Meeting highlights: international consensus panel on the treatment of primary breast cancer J Natl Cancer Inst 87 1441 5 7674331 10.1093/jnci/87.19.1441 1:STN:280:DyaK2MvgsVKntg%3D%3D Goldhirsch A, Wood WC, Senn H-J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995; 87: 1441–5
12. 12. Scrip 1996 26 11 Anon Anon. Novantrone for prostate cancer in the US. Scrip 1996 Nov 26; 17 (No. 2184)
13. 13. PS Wiernik WJ Glidewell HL Hoagland 1979 A comparative trial of daunomycin, ara-c, thioguanine and a combination of the 3 agents for the treatment of acute myelocytic leukaemia Med Pediatr Oncol 6 261 77 381887 10.1002/mpo.2950060311 1:STN:280:DyaE1M3ksVajtg%3D%3D Wiernik PS, Glidewell WJ, Hoagland HL, et al. A comparative trial of daunomycin, ara-c, thioguanine and a combination of the 3 agents for the treatment of acute myelocytic leukaemia. Med Pediatr Oncol 1979; 6: 261–77
14. 14. JW Yates O Glidewell P Wiernik 1982 Cytosine-arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study Blood 60 454 62 6953986 1:STN:280:DyaL383jt1Gmtw%3D%3D Yates JW, Glidewell O, Wiernik P, et al. Cytosine-arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60: 454–62
15. 15. WR Vogler E Velez-Garcia RS Weiner 1992 A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a South Eastern Cancer Study Group study J Clin Oncol 10 1102 11 Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a South Eastern Cancer Study Group study. J Clin Oncol 1992; 10: 1102–11
16. 16. R Bassan T Lerede A Rambaldi 1996 The role of anthracyclines in adult acute lymphoblastic leukaemia Leukemia 10 Suppl.2 S58 61 8649053 Bassan R, Lerede T, Rambaldi A. The role of anthracyclines in adult acute lymphoblastic leukaemia. Leukemia 1996; 10Suppl. 2: S58–61
17. 17. M Levine V Bramwell D Bowman 1995 A clinical trial of intensive CEF versus CMF in premenopausal women with node positive breast cancer Proc Am Soc Clin Oncol 14 103 [abstract] Levine M, Bramwell V, Bowman D, et al. A clinical trial of intensive CEF versus CMF in premenopausal women with node positive breast cancer [abstract]. Proc Am Soc Clin Oncol 1995; 14: 103
18. 18. AP Launchbury N Habboubi 1993 Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity Cancer Treat Rev 19 197 228 8334677 10.1016/0305-7372(93)90036-Q 1:CAS:528:DyaK3sXlvFCqurs%3D Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19: 197–228
19. 19. Y Deveaux C Mathelin S Al-Homsi 1991 Cyclophosphamide (CPM), 5-fluorouracil (5FU) and either doxorubicin (DOX) or theprubicine (THP) (FAC vs FTP) in advanced breast cancer (ABC) — a phase III randomised study Eur J Cancer 27 Suppl.2 S58 [abstract no. 319] Deveaux Y, Mathelin C, Al-Homsi S, et al. Cyclophosphamide (CPM), 5-fluorouracil (5FU) and either doxorubicin (DOX) or theprubicine (THP) (FAC vs FTP) in advanced breast cancer (ABC) — a phase III randomised study [abstract no. 319]. Eur J Cancer 1991; 27Suppl. 2: S58
20. 20. GN Hortobágyi RL Theriault D Frye 1990 Pirarubicin in combination chemotherapy for metastatic breast cancer Am J Clin Oncol 13 Suppl.1 S54 6 2291460 10.1097/00000421-199012001-00012 Hortobágyi GN, Theriault RL, Frye D, et al. Pirarubicin in combination chemotherapy for metastatic breast cancer. Am J Clin Oncol 1990; 13Suppl. 1: S54–6
21. 21. IC Henderson JC Allegra T Woodcock 1989 Randomised clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer J Clin Oncol 7 560 71 2468745 1:STN:280:DyaL1M3hsF2msg%3D%3D Henderson IC, Allegra JC, Woodcock T. Randomised clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560–71
22. 22. CJ Twelves 1995 Oral idarubicin in solid tumour chemotherapy Clin Drug Invest 9 Suppl.2 39 54 Twelves CJ. Oral idarubicin in solid tumour chemotherapy. Clin Drug Invest 1995; 9Suppl. 2: 39–54
23. 23. JM Bennett HB Muss JF Doroshow 1988 A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma J Clin Oncol 6 1611 20 3049953 1:STN:280:DyaL1M%2FhtVyrsg%3D%3D Bennett JM, Muss HB, Doroshow JF, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988; 6: 1611–20
24. 24. RCF Leonard MA Cornbleet SB Kaye 1987 Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056 63 3298559 1:STN:280:DyaL2s3ltlamtA%3D%3D Leonard RCF, Cornbleet MA, Kaye SB, et al. Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. J Clin Oncol 1987; 5: 1056–63
25. 25. JA Neidhart D Gochnour R Roach 1986 A comparison of mitoxantrone and doxorubicin in breast cancer J Clin Oncol 4 672 7 3517241 1:STN:280:DyaL287pvVyhuw%3D%3D Neidhart JA, Gochnour D, Roach R, et al. A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 1986; 4: 672–7
26. 26. A Martoni E Piana M Guaraldi 1990 Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer Oncology 47 427 32 2216299 10.1159/000226863 1:STN:280:DyaK3M%2Fhs1agsg%3D%3D Martoni A, Piana E, Guaraldi M, et al. Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology 1990; 47: 427–32
27. 27. M Lopez A Contegiacomo P Vici 1989 A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer Cancer 64 2431 6 2684383 10.1002/1097-0142(19891215)64:12<2431::AID-CNCR2820641206>3.0.CO;2-1 1:STN:280:DyaK3c%2FlvVequw%3D%3D Lopez M, Contegiacomo A, Vici P, et al. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 1989; 64: 2431–6
28. 28. RP A’Hern ME Gore 1995 Impact of doxorubicin on survival in advanced ovarian cancer J Clin Oncol 13 726 32 7884432 A’Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726–32
29. 29. KS Zuckerman 1994 Efficacy of intensive, high-dose anthracyclinebased therapy in intermediate-and high-grade non-Hodgkin’s lymphomas Semin Oncol 21 Suppl.1 59 64 8153658 1:STN:280:DyaK2c3gsVKksQ%3D%3D Zuckerman KS. Efficacy of intensive, high-dose anthracyclinebased therapy in intermediate-and high-grade non-Hodgkin’s lymphomas. Semin Oncol 1994; 21Suppl. 1: 59–64
30. 30. MC Perry 1991 Complications of chemotherapy AR Moosa SC Schimpff MC Robson Comprehensive textbook of oncology 2 Maryland: Williams & Wilkins Baltimore 1706 19 Perry MC. Complications of chemotherapy. In: Moosa AR, Schimpff SC, Robson MC, editors. Comprehensive textbook of oncology. 2nd ed. Baltimore, Maryland: Williams & Wilkins, 1991: 1706–19
31. 31. K Shan AM Lincoff JB Young 1996 Anthracycline-induced cardiotoxicity Ann Intern Med 125 47 58 8644988 1:STN:280:DyaK283ksFSrsw%3D%3D Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47–58
32. 32. DD Hoff von MW Layard P Basa 1979 Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 710 7 von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979 Nov; 91: 710–7
33. 33. AJ Coukell D Faulds 1997 Epirubicin: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer Drugs 53 3 453 82 9074845 10.2165/00003495-199753030-00008 1:CAS:528:DyaK2sXitFeisr8%3D Coukell AJ, Faulds D. Epirubicin: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 1997; 53(3): 453–82
34. 34. S Legha RS Benjamin B Mackay 1982 Reduction of doxorubicin cardiotoxicity by prolonged continuous IV infusion Ann Intern Med 96 133 9 7059060 1:STN:280:DyaL387jtlentg%3D%3D Legha S, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous IV infusion. Ann Intern Med 1982; 96: 133–9
35. 35. SS Bielack R Erttman B Kempg-Bielack 1996 Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 32A 1652 60 8983270 10.1016/0959-8049(96)00177-3 1:STN:280:DyaK2s7gsFKgsw%3D%3D Bielack SS, Erttman R, Kempg-Bielack B, et al. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 1996; 32A: 1652–60
36. 36. K Helleman 1996 Anthracycline cardiac toxicity by dexrazoxane: breakthrough of a barrier — sharpens antitumour profile and therapeutic index J Clin Oncol 14 2 332 3 [editorial] Helleman K. Anthracycline cardiac toxicity by dexrazoxane: breakthrough of a barrier — sharpens antitumour profile and therapeutic index [editorial]. J Clin Oncol 1996; 14(2): 332–3
37. 37. M Venturini A Michelotti L Maestro Del 1996 Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer J Clin Oncol 14 3112 20 8955656 1:CAS:528:DyaK2sXitl2isQ%3D%3D Venturini M, Michelotti A, Del Maestro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14: 3112–20
38. 38. Physicians’ Desk Reference. Zinecard™. Medical Economics Company, Montvale, NJ, USA; 1996: 1961–3
39. 39. S Kim 1993 Liposomes as carriers of cancer chemotherapy: current status and future prospects Drugs 46 4 618 38 7506649 10.2165/00003495-199346040-00004 1:CAS:528:DyaK2cXhsleitLc%3D Kim S. Liposomes as carriers of cancer chemotherapy: current status and future prospects. Drugs 1993; 46(4): 618–38
40. 40. TM Allen 1997 Liposomes: opportunities in drug delivery Drugs 54 Suppl.4 8 14 9361956 10.2165/00003495-199700544-00004 1:CAS:528:DyaK2sXntlygu70%3D Allen TM. Liposomes: opportunities in drug delivery. Drugs 1997; 54Suppl. 4: 8–14
41. 41. AA Gabizon F Martin 1997 Polyethylene-glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours Drugs 54 Suppl.4 15 21 9361957 10.2165/00003495-199700544-00005 1:CAS:528:DyaK2sXntlygu7o%3D Gabizon AA, Martin F. Polyethylene-glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 1997; 54Suppl. 4: 15–21
42. 42. F Muggia 1997 Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers Drugs 54 Suppl.4 22 9 9361958 10.2165/00003495-199700544-00006 1:CAS:528:DyaK2sXntlygu7s%3D Muggia F. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997; 54Suppl. 4: 22–9
43. 43. D Alberts DJ Garcia 1997 Safety aspects of pegylated liposomal doxorubicin in patients with cancer Drugs 54 Suppl.4 30 35 9361959 10.2165/00003495-199700544-00007 1:CAS:528:DyaK2sXntlygu7g%3D Alberts D, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54Suppl. 4: 30–35
44. 44. AA Gabizon 1994 Liposomal anthracyclines Hematol Oncol Clin N Amer 8 2 431 50 1:STN:280:DyaK2czhsVOnsA%3D%3D Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin N Amer 1994; 8(2): 431–50
45. 45. J Schuller M Czejka S Bandak 1995 Comparison of pharmacokinetics (PK) of free and liposome encapsulated doxorubicin in advanced cancer patients Onkologie 18 Suppl.2 184 Schuller J, Czejka M, Bandak S, et al. Comparison of pharmacokinetics (PK) of free and liposome encapsulated doxorubicin in advanced cancer patients. Onkologie 1995; 18Suppl. 2: 184
46. 46. I Ahmad M Longnecker J Samuel 1993 Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice Cancer Res 53 1484 8 8453612 1:CAS:528:DyaK3sXisVSktrY%3D Ahmad I, Longnecker M, Samuel J, et al. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res 1993; 53: 1484–8
47. 47. TM Allen E Brandeis CB Hansen 1995 A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells Biochem Biophys Acta 1237 99 108 7632714 10.1016/0005-2736(95)00085-H Allen TM, Brandeis E, Hansen CB, et al. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochem Biophys Acta 1995; 1237: 99–108
48. 48. AJ Coukell CM Spencer 1997 Liposomal doxorubicin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of patients with AIDS-related Kaposi’s sarcoma Drugs 53 3 520 38 9074848 10.2165/00003495-199753030-00011 1:CAS:528:DyaK2sXitFeisro%3D Coukell AJ, Spencer CM. Liposomal doxorubicin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of patients with AIDS-related Kaposi’s sarcoma. Drugs 1997; 53(3): 520–38
49. 49. PS Gill J Wernz DT Scadden 1996 Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma J Clin Oncol 14 2353 64 8708728 1:CAS:528:DyaK28XltFSqtrw%3D Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1996; 14: 2353–64
50. 50. FM Muggia JD Hainsworth S Jeffers 1997 Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumour activity and toxicity modification by liposomal encapsulation J Clin Oncol 15 987 93 9060537 1:CAS:528:DyaK2sXitFCgs7k%3D Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumour activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–93
51. 51. PSGJ Hupperets FLG Erdkamp WW Bokkel-Huinink Ten 1996 Phase II study of liposomal encapsulated daunorubicin (DaunoXome) in advanced breast cancer Breast Canc Res Treat 37 76 [abstract 244] Hupperets PSGJ, Erdkamp FLG, Ten Bokkel-Huinink WW, et al. Phase II study of liposomal encapsulated daunorubicin (DaunoXome) in advanced breast cancer [abstract 244]. Breast Canc Res Treat 1996; 37 Suppl.: 76
52. 52. R Lippens 1995 Liposomal daunorubicin in childhood brain tumors, preliminary results of a phase II study Can J Infect Dis 6 Suppl.C 440C [abstract no. 4032] Lippens R. Liposomal daunorubicin in childhood brain tumors, preliminary results of a phase II study [abstract no. 4032]. Can J Infect Dis 1995; 6Suppl. C: 440C
53. 53. E Schmoll H Degen 1995 Liposomal daunorubicin (LD) in hepatocellular carcinoma (HCC) Onkologie 18 Suppl.2 96 [abstract no. 308] Schmoll E, Degen H. Liposomal daunorubicin (LD) in hepatocellular carcinoma (HCC) [abstract no. 308]. Onkologie 1995; 18Suppl. 2: 96